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A B S T R A C T
A relatively simple combination of Schirmer strip sampling with straightforward sensitive nanoLC
quadrupole-Orbitrap tandem mass spectrometry after a minimum of sample processing steps allows for
replicate proteomic analysis of single human tears, i.e., without the requirement for sample pooling. This
opens the way to clinical applications of the analytical workﬂow, e.g., to monitor disease progression or
treatment efﬁcacy within individual patients. Proof of concept is provided by triplicate analyses of a
singular sampling of tears of a dry eye patient, before and one and two months after minor salivary gland
transplantation. To facilitate comparison with the outcome of previously reported analytical protocols,
we also include the data from a typical healthy young adult tear sample as obtained by our streamlined
method.
With 375 conﬁdently identiﬁed proteins in the healthy adult tear, the obtained results are
comprehensive and in large agreement with previously published observations on pooled samples of
multiple patients. We conclude that, to a limited extent, bottom–up tear protein identiﬁcations from
individual patients may have clinical relevance.
ã 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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journal home page: www.elsevier .com/ locat e/euprot1. Introduction
Since the recent launch, within the Human Proteome Organi-
zation (HUPO), of the Human Eye Proteome Project (HEPP) [10,8],
tears are among the body ﬂuids which have gained increasing
interest as a source of diagnostic markers not only for ophthalmo-
logical diseases, but also for systemic and neurological disorders.
Whereas accounts of proteins identiﬁed from human tears all
resulted from the analyses of pooled samples (see advanced LC MS/
MS reports by de Souza et al. [3]; Zhou et al. [15]; Srinivasan et al.
[12]; Salvisberg et al. [11]; and the references quoted therein to
other earlier (and generally less performant) mass spectrometry
based proteomics approaches), we focus on what can be achieved
by studying individual tear samples with the latest LC MS/MS.* Corresponding author at: Department of Biotechnology, Analytical Biotechnol-
ogy & Innovative Peptide Biology Group, Delft, The Netherlands.
E-mail address: p.d.e.m.verhaert@tudelft.nl (P. Verhaert).
http://dx.doi.org/10.1016/j.euprot.2015.06.005
1876-3820/ã 2015 The Authors. Published by Elsevier GmbH. This is an open access aIn order to be compliant with the envisioned clinical applica-
tion, we compiled an efﬁcient analytical workﬂow with minimal
sample preparation steps.
We opted for Schirmer strips (instead of capillaries) as most
convenient clinician friendly tear sampling tools. On these ﬁlter
paper strips >20 ml volumes of tear can be easily collected. This
minimally invasive form of body ﬂuid collection is highly accepted
in the primary healthcare setting and has great potential for use in
health screening [9]. As such it is already common use in current
ophthalmological practice, e.g., for testing the severity of dry eye
disease.
Employing straightforward nanoLC tandem MS by a recently
introduced high resolution quadrupole-Orbitrap hybrid system,
we demonstrate that it is realistically feasible to perform multiple
replicate proteomic analyses (in terms of bottom–up protein
identiﬁcations) on these microliter sample quantities.
As such the overall sensitivity of this optimized analytical
protocol permits intra-individual (unpooled) monitoring of e.g.,
disease progression or treatment, with several hundreds of
relevant data points (protein identiﬁcations and relative quanti-
tations) collected for each clinical sample.rticle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 2
Gradient elution proﬁle (A: Milli Q; B: 80% acetonitrile, 0.1% formic
acid).
Time (min) Flow (nl/min) % A % B
0 350 98 2
40 350 70 30
57 350 35 65
59 350 0 100
60 350 0 100
Table 3
Full scan MS and data dependent MS/MS settings of the Q Exactive PlusTM system.
Abbreviations: AGC, automatic gain control; dd, data dependent; IT, injection time;
NCE, normalized collision energy.
Properties of full scan/dd-MS2
Resolution full MS 70,000
P. Raus et al. / EuPA Open Proteomics 9 (2015) 8–13 9As proof-of-concept we monitored tears of a severe case of
keratoconjunctivitis sicca before and after surgical treatment.
Keratoconjunctivitis sicca, or dry eye syndrome is a very complex
multifactorial disease [7], which, as the name indicates, in virtually
all cases results in reduced tear volume production, which is
reported to be associated with a decreased general lacrimal protein
secretion. Very severe cases are uniquely treated by autotrans-
plantation of a minor salivary gland into the eye, a technique
originally introduced by Prof. J. Murube and perfectionized over
the past ten years [5]. The rationale behind a proteomics analysis of
clinically sampled tears is that comparative protein composition
analysis of tears from diseased versus treated and/or healthy eyes,
may yield medically relevant information regarding both the
effectiveness of the treatment and the possible disease etiology.
2. Materials and methods
2.1. Reagents and chemicals
Ammonium bicarbonate, tris(2-carboxyethyl)phosphine
(TCEP), iodoacetamide, formic acid, dimethyl sulphoxide, as well
as trypsin were from Sigma–AldrichTM.
2.2. Tear collection and sample preparation
Human lacrimal ﬂuids were sampled using Schirmer tear test
strips (Haag-Streit, UK), principally as published earlier by Zhou
et al. [15] and Srinivasan et al. [12]. For this the paper strip was
tenderly placed inside the lower eyelid, after which the subject was
instructed to gently close the eye. The moistened strip was
removed after a maximum of 5 min. The sampling procedure did
not include any anesthetizing eye drops. Both during sampling as
well as further strip handling, gloves were worn.
Two different individuals provided the tear samples used in this
study (Table 1). Tear samples from an individual diagnosed with
severe dry eye syndrome (aqueous deﬁciency subtype) were
collected (with the patient’s consent) at 3 different time points
during disease treatment, i.e., before treatment, and 1, and
2 months after surgery (minor salivary gland transplantation).
Consistent with the data in the literature [12] the aqueous deﬁcient
dry eye typically scored <5 mm of Schirmer strip wetting. For
comparative purposes one additional tear sampling of a healthy
young adult male volunteer was included in this method
evaluation study. Healthy adult tears have been consistently
analyzed by the relevant proteomics methods described in the
literature [3,15,12,11]. The healthy tear easily moistened >15 mm
during sampling.
After sampling, strips were stored in labeled protease-free
Eppendorf vials at 20 C until further analysis. For analysis 2 mm
of the wetted part of the ﬁlter paper area which had not been in
direct contact with the eye ball and conjunctiva (in order to
minimize sample contamination with epithelial proteins) was
carefully cut from each strip. During sample processing, care was
taken to keep the analysis volume to an absolute minimum, toTable 1




Sex Age Clinical origin
Y R M 26 Healthy volunteer
59 R M 69 Dry eye patient (untreated eye)
60 L M 69 Dry eye patient (treated eye, 1 month after
surgery)
61 L M 69 Dry eye patient (treated eye, 2 months after
surgery)remain maximally compatible with the limited nanoLC injection
volume. After transfer to another protease-free microcentrifuge
tube the 2 mm ribbon was carefully cut into minute equally sized
pieces using clean scissors. The resulting shreds were submerged
in 47 ml of 25 mM ammonium bicarbonate (pH 8.0) for 90 min.
Reduction of disulﬁde bonds was achieved by mixing 1 ml of TCEP
(50 stock solution; 10 mM ﬁnal) with the sample for 30 min.
Subsequent alkylation was allowed to occur for 45 min after
addition of 1 ml iodoacetamide (50 stock solution; 20 mM ﬁnal).
Finally overnight protein digestion (RT) was initiated by adding
trypsin (sequencing grade; 1 ml of 200 ng/ml stock). Afterwards
5 ml of a mixture of 5% DMSO and 5% formic acid were added to
assist resuspension of tryptic peptides.
2.3. Sample analysis
Of each sample 5% of the total reaction volume (2.5 ml) were
analyzed by Easy-nLC 1000TM ultra performance liquid chroma-
tography on a 200 mm long in-house packed C18 nano HPLC
column (50 mm ID). A 60 min elution gradient (solvent B: 80%
acetonitrile, 0.1% formic acid; solvent A: Milli Q; 350 nl/min) was
applied as detailed in Table 2.
Tandem MS analysis was carried out on a Q Exactive PlusTM
quadrupole-Orbitrap mass spectrometer (Thermo Fisher Scientiﬁc,
Bremen, Germany). Peptide fragmentation was by high energy
collision induced dissociation (HCD), with the MS2 settings are
summarized in Table 3.
2.4. Data analysis
Spectral ﬁles generated (XcaliburTM, RAW format) were
analyzed using Proteome DiscovererTM software version 1.4.
Multiply charged peptide spectra were deconvoluted to singly
charged spectra and deisotoped. The spectral ﬁles were then
searched against the Uniprot Homo sapiens reference proteome
(UP000005640; release Oct, 2014) using the SequestTM HT
algorithm (Thermo Fisher Scientiﬁc; parameters see Table 4).AGC target full MS 3e6
Maximum IT 250 ms




dd-MS2 max IT 150 ms
Isolation window 2.5 m/z
Fixed ﬁrst mass 100.0 m/z
NCE 28
dd underﬁll ratio 0.5%
Charge exclusion Unassigned, 1, >8
Peptide match Preferred
Dynamic exclusion 30 s
Fig. 1. Numbers of protein groups identiﬁed by nanoUHPLC quadrupole-Orbitrap
MSMS from sub-microliter tear volumes of healthy human volunteer. Triplicate
analysis of a single unpooled individually collected tear sample, yielding an overall








Precursor mass tolerance 5 ppm
Fragment mass tolerance 0.02 Da
Dynamic N-terminal modiﬁcation Gln- > pyro-Glu
Dynamic C-terminal modiﬁcation Amidation
Other dynamic modiﬁcation Oxidation of H,M,W
Static modiﬁcation Carbamidomethyl C
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torTM with a false discovery rate (FDR) <1% and a minimum cross
correlation score (Xcorr) of 2 set as obligatory criteria for conﬁdent
protein identiﬁcation.
To reveal (semi) quantitative trends in tear protein abundances
we employed the basic spectral counting option (summing PSMs
per protein identity) available through the Proteome DiscovererTM
software suite (Thermo Fisher Scientiﬁc, Bremen, Germany).
3. Results and discussion
Since only 5% of the prepared sample, corresponding to less
than 0.5 ml of original tear ﬂuid (equivalent to approximately 4 mg
of total protein), was injected for each one hour LC/MSMS run, a
triplicate analysis could easily be carried out for all individual
samplings.
We here report the obtained number of proteins identiﬁed, as
well as the (semi) quantitation values of some selected (differen-
tial) proteins primarily to illustrate the analysis depth obtainable
on single (unpooled) samples. We refer to the Supplemental
information for the results of all individual analyses.
We also want to mention that MALDI TOF MS data have been
previously reported on individual human tears (e.g., Gonzaléz et al.
[6]). These studies are typically limited to mere proﬁling, lacking
direct protein identiﬁcations.
3.1. Healthy lacrimal ﬂuid
3.1.1. Protein groups in healthy tears
The combined triplicate analysis yields a total of 375 identiﬁed
protein groups, based on a total of 8020 peptide spectral matches
(2506 unique peptides). In spite of the substantial technical
variance of the overall analytical workﬂow (as illustrated in Fig. 1),
out of these, 194 protein groups were consistently identiﬁed in all
3 separate measurements.
3.1.2. Proteins identiﬁed
The protein identiﬁcations agree well with those reported in
earlier tear proteome investigations [3,12,15]. Remarkably our
number of conﬁdently detected proteins in individual tears (375)
does not signiﬁcantly differ from the number (386) identiﬁed from
the combined pooled Schirmer strip samples in the LS MS/MS
study (linear ion trap-orbitrap hybrid; [12]). In comparison the
study of de Souza et al. [3] detected 491 proteins from pooled sets
of capillary collected tears, after combining different sample
preparation methods, including in gel and in solution digestion.
The study by Zhou et al. reported the largest number of human tear
proteins so far (1543), by combining the results of the analysis of
the equivalent of 400 mg of pooled tears by multidimensional HPLC
(SCX followed by nanoRP) on a latest generation quadrupole-TOF
hybrid. More valuable than mere protein numbers, are the protein
identities and (relative) quantities, and with regard to this, our
results are highly comparable with the literature studiesreferenced above. We consistently identiﬁed the most abundant
tear proteins with the largest number of peptides. As an illustration
proteins identiﬁed with >100 peptide spectral matches (PSMs) are
listed in Table 5. The full lists of protein identiﬁcations in all
triplicate samples are included as Supplemental data.
3.2. Diseased lacrimal ﬂuids
3.2.1. Protein groups in patient tears
The untreated condition yielded 126 protein groups (2817 PSMs;
788 unique peptides), the one and two month treated samples
yielded respectively 161 (4261 PSMs; 1162 unique peptides) and
135 protein groups (3605 PSMs; 894 unique peptides). Considering
that these tear analyses were performed on equal volumes of
material (equal size wetted Schirmer strip surface areas) as for the
healthy samples, these data suggest markedly less (minus 50%)
identiﬁable proteins in the diseased tear. Whether or not this lower
number of tear protein identiﬁcations is due to an effect of the age
difference between the donor of the healthy tear sample and the
patient (the amount of tear proteins is known to decrease with age
[14]), to a direct effect of the disease, or to potential disease-
speciﬁc PTMs which were not considered in our typical database
search (Table 4), is not assessed by this study. It shall be clear that
for such inter-individual comparisons a large cohort of properly
matched (sex, age, race, . . . ) donors need to be investigated.
Rather than comparing different individuals, it is much more
appropriate to compare protein compositions within the very
same subject, as we did for the dry eye patient under investigation,
the tears of whom were analysed before and at two time points
after surgical treatment. Thanks to the fact that following the
described workﬂow, a satisfactory analysis depth can be achieved
from unpooled, individual donor samples (see above, healthy
young adult male), such intra-individual comparisons now become
feasible and yield meaningful results. Although the label-free
method for relative protein quantitations has its clear limitations
in terms of accuracy, it is clear that this simple cost-effective and
sample saving approach does have its merit (see Ref. [4], especially
when the purpose is to uncover relative protein abundance trends
rather than to reveal accurate up- or downregulation factors. In
this respect we ﬁnd it interesting to note that proteins which, by
label-free quantitative evaluation, appear originally
Table 5











P61626 Lysozyme C OS = Homo sapiens GN = LYZ PE = 1 SV = 1—[LYSC_HUMAN] 84.46% 1 26 26 433
Q9GZZ8 Extracellular glycoprotein lacritin OS = Homo sapiens GN = LACRT PE = 1 SV = 1—
[LACRT_HUMAN]
43.48% 1 14 14 384
E7ER44 Lactoferrin (Kaliocin-1) OS = Homo sapiens GN = LTF PE = 2 SV = 1—[E7ER44_HUMAN] 74.29% 2 64 64 284
P31025 Lipocalin-1 OS = Homo sapiens GN = LCN1 PE = 1 SV = 1—[LCN1_HUMAN] 78.41% 1 22 22 234
P60709 Actin, cytoplasmic 1 OS = Homo sapiens GN = ACTB PE = 1 SV = 1—[ACTB_HUMAN] 64.53% 2 11 27 217
Q5T8M8 Actin, alpha skeletal muscle OS = Homo sapiens GN = ACTA1 PE = 2 SV = 1—
[Q5T8M8_HUMAN]
45.64% 4 5 22 189
P14618 Pyruvate kinase PKM OS = Homo sapiens GN = PKM PE = 1 SV = 4—[KPYM_HUMAN] 64.03% 2 34 34 150
P06733 Alpha-enolase OS = Homo sapiens GN = ENO1 PE = 1 SV = 2—[ENOA_HUMAN] 65.67% 1 37 37 136
P14555 Phospholipase A2, membrane associated OS = Homo sapiens GN = PLA2G2A
PE = 1 SV = 2—[PA2GA_HUMAN]
71.53% 1 23 23 125
P04083 Annexin A1 OS = Homo sapiens GN = ANXA1 PE = 1 SV = 2—[ANXA1_HUMAN] 80.64% 1 32 32 122
Q09666 Neuroblast differentiation-associated protein AHNAK OS = Homo sapiens
GN = AHNAK PE = 1 SV = 2—[AHNK_HUMAN]
29.86% 1 52 53 110
Q99935 Proline-rich protein 1 OS = Homo sapiens GN = PROL1 PE = 1 SV = 2—
[PROL1_HUMAN]
33.06% 1 8 8 104
P. Raus et al. / EuPA Open Proteomics 9 (2015) 8–13 11downregulated in the untreated diseased state, (re) appear in the
tear with treatment. Unraveling the exact medical/physiological
background of what these observations entail is not the scope of
this paper, but interestingly, several additional agreements with
earlier published semiquantative data are remarkable.
For example, Zhou et al. [14] described a biomarker panel of
proteins the level of which can be correlated with dry eye disease.Table 6
Lysosyme C (P61626, LYSC_HUMAN), lactotransferrin (E7ER44, LTF_HUMAN); lipocalin (P
countings. Note that same color row indicates that sample originated from same individ
whereas any comparison with grayish-green column is an intra-individual (not age-ma
Sample UniProt accession E7ER44 




Lactotransferrin (Kaliocin-1) OS = Homo sapiens GN = LTF PE = 2 SV 
[E7ER44_HUMAN]
Sample UniProt accession P31025 Sum
(co















Lipocalin-1 OS = Homo sapiens GN = LCN1 PE = 1 SV = 1—
[LCN1_HUMAN]
60.
Sample UniProt accession P12273 
Healthy Prolactin-inducible protein OS = Homo sapiens GN = PIP
PE = 1 SV = 1—[PIP_HUMAN]
Diseased
untreated








Prolactin-inducible protein OS = Homo sapiens GN = PIP PE = 1
SV = 1—[PIP_HUMAN]
Sample UniProt accession P61626 Sum
(co
Healthy Lysozyme C OS = Homo sapiens GN = LYZ PE = 1 SV = 1—
[LYSC_HUMAN]
84.










Lysozyme C OS = Homo sapiens GN = LYZ PE = 1 SV = 1—
[LYSC_HUMAN]
84.Although it should be clear that, when considering the number of
representative peptides reﬂecting the protein presence, an inter-
individual comparison of the present limited data set (we here
show only a single non-age matched healthy sample) cannot be
conclusive, it is interesting to note that all 4 biomarker proteins
which Zhou reports as downregulated in dry eye disease (i.e.,
lysozyme, lactotransferrin, lipocalin and prolactin-inducible31025, LCN1_HUMAN); prolactin-inducible protein (P12273, PIP_HUMAN) spectral
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19.86% 1 2 2 7
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19.86% 1 3 3 9









46% 1 26 26 433
08% 1 18 18 142
46% 1 28 28 442
46% 1 28 28 487
Table 7
Protein S100-A9 (P06702, S10A9_HUMAN) spectral countings.










Healthy Protein S100-A9 OS = Homo sapiens GN = S100A9 PE = 1 SV = 1—
[S10A9_HUMAN]
66.67% 1 6 6 26
Diseased Protein S100-A9 OS = Homo sapiens GN = S100A9 PE = 1 SV = 1—
[S10A9_HUMAN]
74.56% 1 8 8 32
One month
treated
Protein S100-A9 OS = Homo sapiens GN = S100A9 PE = 1 SV = 1—
[S10A9_HUMAN]
42.98% 1 4 4 25
Two months
treated
Protein S100-A9 OS = Homo sapiens GN = S100A9 PE = 1 SV = 1—
[S10A9_HUMAN]
42.98% 1 4 4 27
Table 8
Proline-rich proteins 1 and 4 (Q99935, PROL1_HUMAN; Q16378, PROL4_HUMAN) spectral countings.










Healthy Q99935, Proline-rich protein 1 OS = Homo sapiens
GN = PROL1 PE = 1 SV = 2—[PROL1_HUMAN]
33.06% 1 8 8 104
Diseased Q99935, Proline-rich protein 1 OS = Homo sapiens
GN = PROL1 PE = 1 SV = 2—[PROL1_HUMAN]
– – – – –
One month
treated
Q99935, Proline-rich protein 1 OS = Homo sapiens
GN = PROL1 PE = 1 SV = 2—[PROL1_HUMAN]
33.06% 1 5 5 29
Two months
treated
Q99935, Proline-rich protein 1 OS = Homo sapiens
GN = PROL1 PE = 1 SV = 2—[PROL1_HUMAN]
31.85% 1 5 5 39
Healthy Q16378, Proline-rich protein 4 OS = Homo sapiens
GN = PRR4 PE = 1 SV = 3—[PROL4_HUMAN]
28.36% 1 5 5 36
Diseased Q16378, Proline-rich protein 4 OS = Homo sapiens
GN = PRR4 PE = 1 SV = 3—[PROL4_HUMAN]
– – – – –
One month
treated
Q16378, Proline-rich protein 4 OS = Homo sapiens
GN = PRR4 PE = 1 SV = 3—[PROL4_HUMAN]
20.90% 1 2 2 9
Two months
treated
Q16378, Proline-rich protein 4 OS = Homo sapiens
GN = PRR4 PE = 1 SV = 3—[PROL4_HUMAN]
23.88% 1 3 3 30
12 P. Raus et al. / EuPA Open Proteomics 9 (2015) 8–13protein) also appear downregulated in the untreated diseased eye
compared to the healthy eye (of a considerably younger donor).
Moreover. the more appropriate intra-individual comparison
seems to indicate that after treatment the amounts of these
proteins all show a tendency of getting restored (Table 6).
Of the 8 proteins which Zhou reported as upregulated, protein
S100 A9 exhibited the corresponding trend, when comparing the
number of peptides between healthy, diseased and treated eyes
(Table 7).
In view of the nature of the treatment (minor salivary gland
transplantation) it is noteworthy that in the untreated diseased
eye, none of the typical proline rich proteins (PROL1 or PRR4)
described in tears [15] were detected. Both proteins, which are also
known as abundant saliva proteins [1], (re) appear in the treated
eye (Table 8).
In the same context we would like to mention the trend
observed for lacritin. This is known to be a potent secretagogue for
the various tear glands [13], and we previously demonstrated that
minor salivary glands secrete substantial amounts of lacritin [2].
This gave rise to the hypothesis that part of the success of theTable 9
Lacritin (Q9GZZ8, LACRT_HUMAN) spectral countings.
Sample UniProt accession Q9GZZ8 
Healthy Extracellular glycoprotein lacritin OS = Homo sapiens GN = LACRT
PE = 1 SV = 1—[LACRT_HUMAN]
Diseased Extracellular glycoprotein lacritin OS = Homo sapiens GN = LACRT
PE = 1 SV = 1— [LACRT_HUMAN]
One month
treated
Extracellular glycoprotein lacritin OS = Homo sapiens GN = LACRT
PE = 1 SV = 1—[LACRT_HUMAN]
Two months
treated
Extracellular glycoprotein lacritin OS = Homo sapiens GN = LACRT
PE = 1 SV = 1— [LACRT_HUMAN]transplantation surgery could be due to the beneﬁcial effect of
increased lacritin concentration in the treated eye. The present
data are in line with this, as they show a consistent trend when
focusing on the peptide spectral matches for lacritin (Table 9).
Lacritin is detected with more representative peptides in the
healthy versus the dry eye tear, whereas after minor salivary gland
transplantation the number of lacritin peptide spectral matches
steadily increases from 1 to 2 months post surgery.
Another observation (data not detailed) is that various
immunoglobulin chains appear upregulated in the untreated
diseased eye (consistent with inﬂammation), compared to both the
healthy and the treated condition.
4. Concluding remarks
It is evident that the high sensitivity and precision as well as the
robustness of the analytics described above allows one to observe
relevant differences in the protein composition of tears without
the need for sample pooling, thus for each sampling individually.










43.48% 1 14 14 384
34.78% 1 13 13 71
43.48% 1 13 13 114
43.48% 1 17 17 239
P. Raus et al. / EuPA Open Proteomics 9 (2015) 8–13 13combination with extensive standardized (reference) libraries of
identities (as well of quantities) of human tear proteins are
required to enable clinicians to deduce medically or pharmaceuti-
cally pertinent information from nanoUPLC MSMS data acquired
according to the above described protocol. As such this paper is not
a conventional biomarker discovery study, but purely a proof-of-
concept technical note that demonstrates and evaluates the
analytical feasibility for identifying medically relevant proteins
from individual patient samplings of clinically obtained tear ﬂuid.
We moreover show that the workﬂow allows a differential protein
analysis in tear ﬂuid from a single individual during clinical
treatment.
Having shown this, we actually have strong reservations
whether a bottom–up proteomics approach, as in the typical
scientiﬁc literature cited above, i.e., semi-quantitative protein
identiﬁcations per se, is appropriate to provide the physician with
the type of data (biomarker (candidate) s) desired. In many cases
not the mere presence or absence of a gene product, but rather the
(relative) quantities of speciﬁcally modiﬁed proteoforms and/or
protein fragments/peptides will hold the clinically relevant
information, and these are generally not distinguishable in
bottom–up analyses.
We are, therefore, currently optimizing a complementary
(alternative) top–down strategy, which is likewise compatible
with the Schirmer strip sampling method, and which focuses on
the qualitative as well as quantitative analysis of the many
endogenous tear peptides and protein fragments/isoforms which
can be detected by nanoUPLC quadrupole-Orbitrap tandem MS.
Instead of relying on protein identiﬁcations by database searching,
the latter approach much more depends on de novo sequencing.
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